Guiyang Xintian Pharmaceutical Co.,Ltd.

SZSE:002873 Stock Report

Market Cap: CN¥2.0b

Guiyang Xintian PharmaceuticalLtd Future Growth

Future criteria checks 4/6

Guiyang Xintian PharmaceuticalLtd is forecast to grow earnings and revenue by 23.8% and 15.7% per annum respectively. EPS is expected to grow by 23.8% per annum. Return on equity is forecast to be 9.1% in 3 years.

Key information

23.8%

Earnings growth rate

23.8%

EPS growth rate

Pharmaceuticals earnings growth18.4%
Revenue growth rate15.7%
Future return on equity9.1%
Analyst coverage

Low

Last updated18 Apr 2024

Recent future growth updates

No updates

Recent updates

Earnings Tell The Story For Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) As Its Stock Soars 25%

Oct 01
Earnings Tell The Story For Guiyang Xintian Pharmaceutical Co.,Ltd. (SZSE:002873) As Its Stock Soars 25%

Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

Jun 05
Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio

Weak Statutory Earnings May Not Tell The Whole Story For Guiyang Xintian PharmaceuticalLtd (SZSE:002873)

Apr 19
Weak Statutory Earnings May Not Tell The Whole Story For Guiyang Xintian PharmaceuticalLtd (SZSE:002873)

Investors Still Aren't Entirely Convinced By Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) Earnings Despite 28% Price Jump

Mar 11
Investors Still Aren't Entirely Convinced By Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) Earnings Despite 28% Price Jump

Earnings and Revenue Growth Forecasts

SZSE:002873 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,339134N/A2651
12/31/20251,192116N/A-711
12/31/20241,063101N/A2401
6/30/20248706543125N/A
3/31/2024923711899N/A
12/31/202395481-2478N/A
9/30/202399494-4849N/A
6/30/20231,089100-9017N/A
3/31/20231,047106-4272N/A
1/1/20231,088112-5376N/A
9/30/20221,094117-8390N/A
6/30/20221,040111-54109N/A
3/31/20221,004106-29111N/A
1/1/202297010119124N/A
9/30/2021954102101173N/A
6/30/202190296105174N/A
3/31/20218659689157N/A
12/31/202075174108176N/A
9/30/2020726633396N/A
6/30/202071162-5059N/A
3/31/202071257-11539N/A
12/31/201977371-12234N/A
9/30/201976176-10141N/A
6/30/201973973-1476N/A
3/31/2019700712676N/A
12/31/201869471748N/A
9/30/2018678692155N/A
6/30/201867769-4753N/A
3/31/201869168N/A38N/A
12/31/201768266N/A62N/A
9/30/201768067N/A69N/A
6/30/201766562N/A55N/A
3/31/201764160N/A75N/A
12/31/201663357N/A61N/A
9/30/201661559N/A65N/A
6/30/201656541N/A63N/A
3/31/201653641N/A52N/A
12/31/201552242N/A41N/A
9/30/201550944N/A42N/A
6/30/201549647N/A44N/A
3/31/201547540N/A41N/A
12/31/201445433N/A37N/A
12/31/201340615N/A18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002873's forecast earnings growth (23.8% per year) is above the savings rate (2.9%).

Earnings vs Market: 002873's earnings (23.8% per year) are forecast to grow faster than the CN market (23.7% per year).

High Growth Earnings: 002873's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 002873's revenue (15.7% per year) is forecast to grow faster than the CN market (13.4% per year).

High Growth Revenue: 002873's revenue (15.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 002873's Return on Equity is forecast to be low in 3 years time (9.1%).


Discover growth companies